Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for TCM Biotech International's Debt-to-EBITDA or its related term are showing as below:
TPE:4169'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.43 Med: 3.02 Max: 7.45
Current: 2.08
During the past 13 years, the highest Debt-to-EBITDA Ratio of TCM Biotech International was 7.45. The lowest was 0.43. And the median was 3.02.
TPE:4169's Debt-to-EBITDA is ranked worse than 59.8% of 296
companies
in the Biotechnology industry
Industry Median: 1.15
vs TPE:4169: 2.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
TCM Biotech International Debt-to-EBITDA Related Terms
TCM Biotech International Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4169 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, TCM Biotech International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
TCM Biotech International (TPE:4169) has a Debt-to-EBITDA of -0.30 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TCM Biotech International. Over the past decade, TCM Biotech International's Debt-to-EBITDA has ranged from 0.43 to 7.45. According to the industry distribution chart, TCM Biotech International ranks #177 out of 296 companies in the Biotechnology industry, placing it in the top 59.8%.
Is TCM Biotech International's Debt-to-EBITDA too high?
TCM Biotech International's current Debt-to-EBITDA is -0.30. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 7.45. Based on the distribution chart, TCM Biotech International ranks #177 out of 296 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #177 out of 296 companies for Debt-to-EBITDA. This places TCM Biotech International in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. Historically, TCM Biotech International's own Debt-to-EBITDA has ranged from 0.43 to 7.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TCM Biotech International. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current Debt-to-EBITDA is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current Debt-to-EBITDA is -0.30. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Debt-to-EBITDA is -0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
Debt-to-EBITDA: -0.30
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
